Tehran University of Medical Sciences Acta Medica Iranica 0044-6025 58 8 2020 11 10 400 403 EN Bita Eslami Breast DiseasesResearch Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran Amirmohsen Jalaeefar Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran Ashraf Moini Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Gynecology and Obstetrics, Arash Women's Hospital, Tehran University of Medical Sciences, Tehran, Iran. AND Department of Endocrinology and Female Infertility at Reproductive Biomedicine Research Center, Royan Institute for Reproductive Biomedicine, ACECR, Tehran, Iran. Ramesh Omranipour Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Surgical Oncology, Cancer Institute, Tehran University of Medical Sciences, Tehran, Iran. Maryam Haghighi Breast Oncology Clinic, Cancer Institute, Imam Khomeini Hospital Complex, Tehran University of Medical Sciences, Tehran, Iran Sadaf Alipour Breast Diseases Research Center (BDRC), Tehran University of Medical Sciences, Tehran, Iran. AND Department of Surgery, Arash Women’s Hospital, Tehran University of Medical Sciences, Tehran, Iran. 2020 02 26 2020 05 04 Fertility preservation counseling has a high priority in young breast cancer (BC) patients. Cytotoxic chemicals used for chemotherapy in these patients increased the risk of premature ovarian failure. This study evaluated the anti-mullerian hormone (AMH) level at the time of diagnosis and within a month after the end of chemotherapy, while predicting the time of the return of ovarian function in BC cases (n=46) younger than 46 years for the first time in Iran. Cases were selected from those attending the breast oncology clinic of the two hospitals with a newly diagnosed in situ or invasive BC. The present study results showed AMH levels were significantly decreased in almost all women within a month after chemotherapy. It seems that the need for fertility preservation depends on patient age and baseline AMH level, but counseling should be offered by the clinician in young breast cancer patients. https://acta.tums.ac.ir/index.php/acta/article/view/8337